Russia's COVID-19 vaccine to enter production, deliver first batch of doses in two weeks

The vaccine is given in two doses and will help people develop immunity to the virus for at least two years.

tech2 News Staff August 12, 2020 17:17:32 IST
Russia's COVID-19 vaccine to enter production, deliver first batch of doses in two weeks

It was just yesterday that the world's first vaccine registered by Russian authorities, and now the World Health Organisation has said it is in talks with Russia's health ministry for a thorough review of the safety and efficacy of the vaccine, called Sputnik V.

While there was no timeline given to how long this review process might take, in under 24 hours, the health minister Mikhail Murashko has announced that mass production of the vaccines has already begun.

According to a report by Sputnik News, the first batch of the Sputnik V vaccine will be produced in two weeks time, and delivered to Russian hospitals. Mass production has reportedly begun at the factory of Russian pharma company AFK Sistema's Binnopharm. A total of 500 million doses are expected to be made in the first 12 months of the production process.

Alexander Gintsburg, director of the Gamaleya Institute said, "Russia plans to be able to produce 5 million doses a month by December-January."

Earlier, Industry and Trade Minister Denis Manturov had said in an interview with TASS said that the Gamaleya Institute is working with three Russian companies – Generium, R-Pharm and Binnopharm – who have facilities in the Vladimir, Yaroslavl and Moscow regions. He also said production was to start in September with 'several thousands of doses' being produced each month in 2020 and 'several million' doses by 2021.

Murashko also said, "today, quality control tests are underway. Within two weeks, the first batch of the drug will be released and will be delivered for [vaccination of] medics in health risk groups".

Also Read: Germany, India, US, even fellow Russians sceptical of COVID-19 vaccine

The Sputnik V vaccine

The vaccine has been developed by the Gamaleya Institute along with Russia’s Defense Ministry uses a different virus - the common cold-causing adenovirus – that’s been modified to carry genes for the “spike” protein that coats the coronavirus, as a way to prime the body to recognize if a real COVID-19 infection comes along.

The vaccine is similar to others being developed by China’s CanSino Biologics and Britain’s Oxford University and AstraZeneca.

The vaccine is supposedly given in two doses, and will help people develop immunity to the virus for at least two years. For now, the vaccine being produced will be used to meet the demands in Russia. However, Murashko said he cannot rule out exporting the vaccine as yet. While many countries are sceptical of the vaccines, still others have begun talks with Russia to either get the vaccine or conduct human trials in their countries.

The vaccine will be given to people who volunteer for it including doctors. Previously, frontline works and teachers were said to be the first in line for the vaccine's initial doses and it would be administered free of charge.

Also Read: Russia launches world’s first registered COVID-19 vaccine 'Sputnik V' today: Here's all you need to know

Tracing app

A Sputnik News report also mentioned a 'tracing app' that is being developed that will 'allow Russian citizens to confirm the state of their health' and also allow scientists to 'monitor possible adverse effects of the drug for those who took the vaccine.'

Also Read:

Russia's 'Sputnik V' COVID-19 vaccine: WHO in close contact with Russian health ministry for 'rigorous review' of safety, efficacy data

Philippines to conduct human trials of Russia's COVID-19 vaccine; Prez claims he has 'huge trust' in the shot

Far from awe-inspiring Sputnik launch in 1957, Russia's COVID-19 vaccine met with concerns about science, safety

Updated Date:

also read

Covaxin, Bharat Biotech's COVID-19 vaccine candidate, gets DCGI nod for Phase 3 trials
India

Covaxin, Bharat Biotech's COVID-19 vaccine candidate, gets DCGI nod for Phase 3 trials

The phase 3 trials will be conducted in 19 sites across 10 states, including in cities such as Delhi, Mumbai, Patna and Lucknow and would seek to enroll 28,500 volunteers aged 18 years and above.

Anika Chebrolu, 14-year-old Indian-American girl, wins $25,000 for her COVID-19 cure research
science

Anika Chebrolu, 14-year-old Indian-American girl, wins $25,000 for her COVID-19 cure research

The 14-year-old began working on ways to fight the seasonal flu. But her plans changed when the pandemic hit.

Centre says COVID-19 vaccine distribution via 'special immunisation programme'; active cases remain under 7 lakh
India

Centre says COVID-19 vaccine distribution via 'special immunisation programme'; active cases remain under 7 lakh

The Union health ministry also said that the number of new cases reported in the country remained below 60,000 for the fifth consecutive day